Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy

20 Mar 2025

Abstract excerpt

In addition to classic small-molecule drugs and modern protein-based biologics, an intriguing class of medicines is the therapeutic oligonucleotides. Most approved drugs in this category are antisense oligomers or those acting via RNA interference, both of which use base hybridization. Aptamers, also known as chemical antibodies form a smaller, yet equally interesting group of oligonucleotides that can recognize...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40143057
DOI: 10.3390/pharmaceutics17030394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in TherapyPMID 40143057Read ↗

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in OphthalmologySemantic proximity Read ↗

Nucleic Acid-Based Aptamers: Applications, Development and Clinical TrialsSemantic proximity Read ↗

Identification and Engineering of Aptamers for Theranostic Application in Human Health and DisordersSemantic proximity Read ↗

Aptamer-Based Probes for Cancer Diagnostics and TreatmentSemantic proximity Read ↗

Therapeutic Applications of AptamersSemantic proximity Read ↗

Aptamers and antibodies: rivals or allies in cancer targeted therapy?Semantic proximity Read ↗

Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic FrontiersSemantic proximity Read ↗

Antisense oligonucleotide: A promising therapeutic option to beat COVID ‐19Semantic proximity Read ↗

Anti‐VEGF DNA‐based aptamers in cancer therapeutics and diagnosticsSemantic proximity Read ↗

Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and BeyondSemantic proximity Read ↗

FDA-Approved Oligonucleotide Therapies in 2017Semantic proximity Read ↗

Aptamers: An Emerging Class of Molecules That Rival Antibodies in DiagnosticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.